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Apoptosis is an important defensemechanismmounted by the immune system to control
virus replication. Hence, cytomegaloviruses (CMV) evolved and acquired numerous
anti-apoptotic genes. The product of the human CMV (HCMV) UL36 gene, pUL36 (also
known as vICA), binds to pro-caspase-8, thus inhibiting death-receptor apoptosis and
enabling viral replication in differentiated THP-1 cells. In vivo studies of the function of
HCMV genes are severely limited due to the strict host specificity of cytomegaloviruses,
but CMV orthologues that co-evolved with other species allow the experimental study
of CMV biology in vivo. The mouse CMV (MCMV) homolog of the UL36 gene is called
M36, and its protein product (pM36) is a functional homolog of vICA that binds to
murine caspase-8 and inhibits its activation. M36-deficient MCMV is severely growth
impaired in macrophages and in vivo. Here we show that pUL36 binds to the murine
pro-caspase-8, and that UL36 expression inhibits death-receptor apoptosis in murine
cells and can replace M36 to allow MCMV growth in vitro and in vivo. We generated a
chimeric MCMV expressing the UL36 ORF sequence instead of the M36 one. The newly
generatedMCMVUL36 inhibited apoptosis inmacrophage lines RAW264.7, J774A.1, and
IC-21 and its growth was rescued to wild type levels. Similarly, growth was rescued in vivo
in the liver and spleen, but only partially in the salivary glands of BALB/c and C57BL/6
mice. In conclusion, we determined that an immune-evasive HCMV gene is conserved
enough to functionally replace its MCMV counterpart and thus allow its study in an in vivo
setting. As UL36 and M36 proteins engage the same molecular host target, our newly
developed model can facilitate studies of anti-viral compounds targeting pUL36 in vivo.
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INTRODUCTION
Human cytomegalovirus (HCMV), a member of the
betaherpesvirus family, retains global endemic status, with
infection rates ranging from 30% in industrialized countries
to more than 90% in developing ones (Manicklal et al.,
2013). HCMV infection induces mild or no symptoms in
immunocompetent people, yet the immunocompromised or
immunodeficient ones suffer severe bouts of HCMV-related
disease due to virus reactivation or de novo infection. Antivirals
like gancyclovir or foscarent, are staple therapy against
HCMV, yet all approved drugs act by inhibiting viral DNA
polymerization, prompting the selection of resistant mutants
and impairing our ability to use them in combination therapy.
Therefore, identifying and validating additional molecular
targets in HCMV-infected cells remains a clinically important
goal.
Due to its strict host specificity, HCMV cannot infect non-
human cells. Hence, the study of HCMV biology is limited to
in vitro models of infection (Kim and Carp, 1972; Lafemina
and Hayward, 1988; Tang and Maul, 2006), or to the study
of HCMV homologs that coevolved with other animal species.
The mouse homolog of HCMV is the mouse cytomegalovirus
(MCMV), and it provides a widely used tool to study the CMV
biology in vivo (Reddehase et al., 2002). However, the study of
the function of individual MCMV genes does not necessarily
reflect the molecular interaction of orthologous HCMV-encoded
gene products and target molecules within human host-cells.
Therefore, molecular interactions between MCMV proteins and
their ligands may not be extrapolated to define molecular targets
of HCMV infection. Similarly, chimeric MCMVs expressing
HCMV genes instead of the MCMV orthologue gene showed
impaired replication, (Wagner et al., 2000; Farrell et al., 2011)
limiting their use as tools to study the function of HCMV genes
in vivo.
Apoptosis is a complex mechanism that was originally defined
as programmed cell death characterized by cell shrinkage,
pyknosis, DNA fragmentation and plasma membrane blebbing
(Kerr et al., 1972). The two major apoptosis pathways are the
mitochondrial and the death-receptor apoptosis, responding to
cell-intrinsic or to extrinsic stimuli, respectively (Galluzzi et al.,
2012). The intrinsic mitochondrial apoptosis can be triggered
by a plethora of stress signals that converge at the level of
engagement of proteins of the Bcl2 family in the mitochondrion
(Kroemer et al., 2007). The extrinsic apoptosis pathway, on
the other hand, is initiated by extracellular ligands that bind
to receptors of the tumor necrosis factor (TNF) superfamily.
Either pathway leads to the activation of cysteine-aspartic acid
proteases called caspases, which mediate a cascade of signals
culminating in DNA fragmentation and cell death (Ashkenazi
and Dixit, 1998). CD95 (also known as Fas or Apo1) is the
best characterized member of the tumor necrosis factor (TNF)
receptor gene superfamily (Huttmann et al., 2015). The death
receptors undergo homo-trimer formation upon binding of the
corresponding death ligand, which recruits the adaptor protein
FADD (Fas-associated death domain) (Chinnaiyan et al., 1995),
activating caspase-8, and initiating the caspase signaling cascade.
Caspase-8 auto-catalytically cleaves itself, which releases it from
the death-initiation signaling complex (DISC) into the cytosol,
where it acts on downstream effector caspases, like caspase-
3, and commits the affected cell to apoptosis (Muzio et al.,
1998).
Intrinsic apoptosis is employed as a cell autonomous defense
mechanism that restricts the spread of viruses. Similarly,
immune cells also induce apoptosis via death receptor signaling
(Ashkenazi and Dixit, 1998). Consequently, the ability to
inhibit cell death confers survival advantage to the viruses
that have evolved antiapoptotic viral genes. Multiple genes
disrupting diverse apoptotic signaling pathways (Goldmacher
et al., 1999; Brune et al., 2001, 2003; Skaletskaya et al., 2001;
Menard et al., 2003) have been identified in the case of
cytomegaloviruses. The importance of antiapoptotic genes is
highlighted by the remarkable conservation of viral antiapoptotic
proteins among different cytomegaloviruses (Mccormick et al.,
2003). TheHCMV viral Inhibitor of Caspase-8 Activation (vICA)
is encoded by the UL36 gene. The mouse cytomegalovirus gene
M36 is the positional orthologue of UL36 and it has 23%
amino acid identity to UL36 (Skaletskaya et al., 2001; Menard
et al., 2003). Both of these genes encode proteins that inhibit
death receptor mediated apoptosis by binding to caspase-8 and
inhibiting its activation (Skaletskaya et al., 2001; Menard et al.,
2003; Cicin-Sain et al., 2008). MCMV mutants lacking M36
(1M36.MCMV) show growth defects in cultured macrophages,
which undergo apoptosis upon infection (Menard et al., 2003;
Cicin-Sain et al., 2008). Similarly, the UL36 gene is required
for HCMV growth in THP-1 derived macrophages, but it
inhibited both the apoptotic, as well as the non-apoptotic cell
death pathways (Mccormick et al., 2010). We have previously
identified the M36 gene as a determinant of viral fitness in
vivo and shown that this fitness and apoptosis inhibition are
restored in a 1M36 MCMV by the expression of a dominant-
negative FADD gene (Cicin-Sain et al., 2008). More recently,
it was shown that the molluscum contagiosum gene MC159
may also replace the M36 function and protect the virus from
apoptosis, and improve its replication fitness in macrophages,
albeit not completely (Huttmann et al., 2015). We also showed
that macrophages are major immune system cells that control the
growth of 1M36.MCMV (Ebermann et al., 2012). The sequence
and functional homology of M36 and UL36 may advocate a
possible in vivo protective function of the UL36 gene, but this
could not be confirmed, due to the aforementioned strict HCMV
host specificity.
Here we show that the UL36 gene can inhibit death receptor
mediated apoptosis in murine cells. We generated a chimeric
MCMV virus, where the M36 open reading frame (ORF) was
replaced with the UL36 ORF. We demonstrated that UL36
replaces the function of M36 in MCMV infection. While
1M36.MCMV showed a severe loss of fitness in macrophages
and in vivo, the expression of UL36 rescued the viral growth.
Furthermore, UL36 was bound to caspase-8 in murine cells and
blocked apoptosis. Taken together, our data indicate that UL36
and M36 share sufficient functional homologies to enable them
to engage the highly conserved cellular target proteins across host
species.
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MATERIALS AND METHODS
Mouse Strains
All animal experiments were conducted according to guidelines
defined by the Federation of Laboratory Animal Science
Associations and the national animal welfare body Gesellschaft
für Versuchstierkunde/Society of Laboratory Animals. C57BL/6
and BALB/c mice were purchased from Janvier (Le Genest St
Isle, France). The experimental procedures were approved by the
responsible state office (Lower Saxony State Office of Consumer
Protection and Food Safety) under permit no. 33.19-42502-04-
12/0838.
Cells and Viruses
HEK293, IC-21, J774A.1, M2-10B4, NIH3T3, and RAW 264.7
cells were purchased from American Type Culture Collection.
HEK293, J774A.1, M2-10B4, NIH3T3, and RAW 264.7 cells
were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) with supplements (10% FCS, 2 mM L-glutamine, 100
IU/mL penicillin and 100 µg/mL streptomycin). IC-21 cells
were maintained in RPMI-1640 medium with above stated
supplements. The primary C57BL/6 mouse embryo fibroblasts
(MEFs) were prepared and maintained as described earlier
(Podlech et al., 2002). The wild type virus MCMVWT is pSM3fr-
MCK-2fl derived from Smith strain (Jordan et al., 2011). The
recombinant MCMVUL36 and 1M36.MCMV were generated
with lambda red-mediated markerless recombination (Tischer
et al., 2010; Jordan et al., 2011). The 1M36.MCMV virus was
generated by replacing the start codon and methionine codon in
exon 1 of M36 ORF, at position 49,270 and 49,090 respectively,
with stop codons. The MCMVUL36 virus was generated by
replacing the M36 gene in MCMV genome with the UL36 gene
in a manner that M36 exons were replaced with UL36 exons
in two successive recombination rounds while the M36 intron
was left unchanged. The UL36 ORF exons were amplified from
HCMV strain Merlin (Dolan et al., 2004). Briefly, the En Passant
insertion cassettes were generated by cloning UL36 exons around
a kanamycin resistance gene and a I-SceI recognition site, which
were then amplified using homology primers corresponding
to the insertion site in the MCMV genome. This linear DNA
was transformed in the electrocompetent and recombination
competent GS1783 bacteria harboringMCMVBAC. The bacteria
were spread on kanamycin supplemented LB agar plates to
select the positive clones and incubated overnight at 32◦C.
On the following day, the colonies were selected and screened
with colony PCR and the sequence was confirmed by Sanger
sequencing of the target region. The viruses were recovered by
transfecting C57BL/6 MEFs with virus BAC using FuGENE R©
HD (Promega, CA, USA). Viruses were propagated on M2-10B4
cells and virus stocks were prepared by purification using sucrose
cushion as described previously (Menard et al., 2003; Jordan et al.,
2011). The virus titers were quantified by plaque assay as PFU/mL
using C57BL/6 MEFs.
Illumina Sequencing
The MCMVWT and MCMVUL36 BAC DNA was sheared by
sonication and the NEBNext R© Ultra kit was used for the DNA
library preparation. The sequencing was performed on Illumina
MiSeq platform. The whole genome DNA sequencing data was
analyzed by alignment to reference genome using Burrows-
Wheeler Aligner MEM algorithm (Li and Durbin, 2009). The
mutations were called using samtools (Li et al., 2009) and
VarScan 2 (Koboldt et al., 2012). The parameters used to call
mutations (both SNPs and Indels) from aligned sequence were:
minimum basecall quality (>20), read depth (≥20) and variant
frequency threshold (>1%).
Plasmids and transfection
Cloning was performed using mammalian expression vector
pEBFP-N1, where EBFP gene was deleted and mNeon and
N-terminus myc tagged UL36 were inserted using seamless
cloning as described earlier (Gibson et al., 2009). The newly
developed vector was named mNeon-P2A-mycTAG-UL36-N1
and empty vector was mNeon-N1. HEK293 and NIH3T3 cells
were transfected using FuGENE R© HD reagent (Promega, CA,
USA) according to manufacturer’s guidelines.
In vitro Infection and Virus Quantification
Cells were seeded at a defined density one day before infection.
On the day of infection, the cells were infected at the required
MOI. After 1 h the virus was removed and the cells were washed
with 1X PBS and then given fresh growth medium. The growth
curves in IC-21, J774A.1, and RAW 264.7 cells were determined
by seeding 50,000 cells per well in 24 well plates. The cells were
infected the following day, with an MOI of 1 for IC-21 and
J774A.1 and an MOI of 2.5 for RAW 264.7. The supernatants
were collected on 6 consecutive days and titrated on C57BL/6
MEFs as described previously (Cicin-Sain et al., 2005).
In vivo Infection and Virus Quantification
Six to eight week-old BALB/c and C57BL/6 mice were inoculated
with 2 × 105 and 106 PFU, respectively, via the intraperitoneal
route, of cell culture-grown and sucrose cushion-purified virus.
The mice were housed in specific pathogen free conditions and
sacrificed by CO2 asphyxiation on day 5 or day 21. Spleen, lungs,
liver and salivary glands were collected aseptically and stored
in 1 mL medium (DMEM supplemented with 5% FCS, 2 mM
glutamine, 100 IU/mL penicillin and 100 µg/mL streptomycin)
at −80◦C. Organs were homogenized in 5 ml of DMEM
(supplemented with 5% FCS, 2 mM glutamine, 100 IU/mL
penicillin and 100 µg/mL streptomycin) on 100 µm-pore-size
cell strainers. Organ homogenates were used for titration on
C57BL/6 MEFs as described above.
Reverse Transcription Polymerase Chain
Reaction (RT-PCR)
NIH3T3 cells were infected with MCMVWT and MCMVUL36 at
an MOI of 1.0. The mRNA was isolated with Magnetic mRNA
isolation kit (New England BioLabs) according to manufacturer’s
instructions. DNase I treated mRNA was used to produce the
cDNA by SuperScript R© II Reverse Transcriptase (Thermo Fisher
Scientific) using the oligo dT primer. Reverse transcription PCR
was performed with UL36Exon2-seq-F2 (5′-TTTTTTGGGATG
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 3 July 2017 | Volume 7 | Article 312
Chaudhry et al. UL36 Replaces M36 Function In vivo
TTGACAGGTG-3′) and UL36Exon2-seq-R3 (5′-GCCCACCAT
GAAGGATTTTC-3′) primers yielding a 604 bp product.
Apoptosis Assay
Apoptosis was induced inHEK293 andNIH3T3 cells by exposing
the cells to 100 ng/mL CD95L and 10 µg/mL cycloheximide
(CHX). Active caspase-3 was stained with either FITC or PE
labeled anti-active caspase-3 antibodies (BD-Clone C92-605),
following CD95L induced apoptosis in HEK293 and NIH3T3, or
virus induced apoptosis in murine macrophage cell lines. The
protocol used for active caspase-3 staining was adopted from
Cicin-Sain et al. (2008). Briefly, cells were gently scraped and
pelleted by spinning at 500 g for 5 min and then washed once
with PBS. The cells were then re-suspended in 450 µL PBS
and fixed by adding 50 µL fixation buffer (eBioscience). This
was followed by autofluorescence quenching in 50 mM NH4Cl-
PBS (500 µL) for 30 min at room temperature. Cells were then
stained by suspending them in 100 µL permeabilization solution
(eBioscience) and 20 µL antibody solution, and incubated for
1 h in darkness at room temperature. After staining, the cells
were washed once and then suspended in FACS buffer. The cells
were then acquired in a flow cytometer and analyzed with FlowJo
software.
For annexin V staining the cells were harvested as described
in previous paragraph. After washing, cells were suspended
in 250 µL 1X Annexin V binding buffer (BD, NJ, USA)
containing 5 µL of APC labeled Annexin V (BD, NJ, USA).
The cells were incubated at room temperature for 30 min
and acquired directly in Annexin V binding buffer by flow
cytometer.
Co-immunoprecipitation (Co-IP)
For co-immunoprecipitation of endogenous caspase-8 with
UL36, NIH3T3 cells were transfected with myc-tagged UL-36.
Cells were harvested 48 h post transfection and lysed in TPNE
buffer (buffer 1% v/v Triton X-100, 300 mM NaCl, 8.1 mM
Na2HPO4, 2.7 mM KCl, 1.5 mM K2HPO4, 2 mM EDTA, 10
mM NaF, 1 mM PMSF, 5 µg/ml apotinin, 5 µg/ml leupeptin,
5 µg/ml pepstatin A, 5 µg/ml chymostatin, 1 mM Na3VO4,
pH7.4). Extracts were incubated overnight at 4◦C with 2 µg
of anti-myc antibody (#9402, Cell Signaling Technology) in the
presence of magnetic Protein G beads (Thermo Fisher Scientific).
Subsequently, precipitates were washed, denatured and eluted
according to the manufacturer’s instructions. Proteins were
separated on a 12% polyacrylamide gel. For further analysis, the
proteins were blotted onto a polyvinylidene difluoridemembrane
(GE Healthcare), probed with antibodies against caspase-8
(1G12; Enzo), α tubulin (DM1A, Thermo Fisher Scientific) and
UL36 (Center for Proteomics, University of Rijeka, Croatia)
and developed with ECL Select chemiluminescence reagent (GE
Healthcare).
RESULTS
UL36 Inhibits Apoptosis in Murine Cells
A caspase-3 activation assay was used to evaluate if UL36 can
inhibit apoptosis in murine cells. NIH3T3 murine cells were
transiently transfected with a plasmid expressing UL36, and
apoptosis was induced by treating the cells with recombinant
CD95L. As control, we transfected the human cell line HEK293
with the same UL36 vector to compare the extent of apoptosis
inhibition in human and murine cells. Apoptosis was measured
by intracellular staining with fluorophore-coupled antibodies
against the active caspase-3, followed by flow-cytometry.
Approximately 40–50% of the mock-transfected HEK293 cells
showed apoptosis, but UL36-transfection substantially improved
viability (Figure 1A). UL36 also inhibited apoptosis in the
murine NIH3T3 cells, where a threefold reduction was observed,
similar to the one observed in HEK293 cells (Figure 1).
Generation and characterization of the
recombinant MCMVUL36
To examine if UL36 can functionally replace M36 and inhibit
apoptosis in the context of virus infection, the MCMVUL36 virus
was generated. M36 and UL36 gene have two exons, where
the first exon is smaller and the second one is comparatively
larger (Skaletskaya et al., 2001; Cicin-Sain et al., 2005). The
intron of the HCMV gene UL36 encodes an miRNA called
miRUL36 that inhibits apoptosis in human cells (Guo et al.,
2015). Thus, to exclude that any anti-apoptotic activity in the
chimeric virus would be due to changes in the non-coding
introns, rather than in the exons, MCMVUL36 was generated by
replacing M36 ORF with that of UL36 in a way that exons of the
M36 gene were replaced with UL36 exons and the M36 intron
with splice donor and acceptor sites was not altered (Figure 2A).
The chimeric virus was generated using BAC-based two-step
traceless homology recombination and the whole sequence of
the recombinant BAC was analyzed by Illumina next generation
sequencing (NGS), where no unwanted mutations, either in
the target region or off-target, were found (data not shown).
The virus was recovered by transfecting NIH3T3 cells with
recombinant BAC and the virus fitness was initially tested in vitro
by multistep growth curve in fibroblasts. NIH3T3 fibroblast cells
were infected with the recombinant virus and its growth kinetics
were compared with that of wild-type virus. The growth pattern
of both viruses was very similar, arguing for no fitness loss in
cultured fibroblasts (Figure 2B), which was in line with the lack
of off-target mutations observed by NGS. RT-PCR and western
blot were used to confirm the gene expression of the UL36 from
the MCMVUL36. Since the UL36 gene was inserted under the
control of the M36 promotor, its transcription and translation
was anticipated to reflect the pattern of M36 expression. UL36
expression was validated on day 1 post infection in NIH3T3 cells
infected with MCMVUL36 at an MOI of 1.0. The transcription
of the gene was verified by analyzing the mRNA of infected cells
by RT-PCR with primers specific for UL36 exon 2 (Figure 2C).
Protein expression of UL36 by the recombinant virus was
confirmed with western blot as shown in Figure 2D, using anti-
UL36 monoclonal antibodies that detected the 52 KDa pUL36
protein band. No signal was detected in the 1M36.MCMV
or MCMVWT infected cells (Figure 2D), confirming that the
antibodies specifically detected pUL36 and did not cross-react
with the M36 protein.
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FIGURE 1 | UL36 inhibits apoptosis in Murine NIH3T3 cells. HEK293 (A) and NIH3T3 (B) cells were transfected with UL36 expressing vector and empty vector.
Apoptosis was induced with CD95L 24 h post transfection and the cells were labeled with PE coupled anti-active caspase-3 1 day after stimulation with CD95L, this
was followed by flow cytometric analysis. (*p < 0.05, Kruskall-Wallis test with Dunns post-analysis). (C) Representative contour plots of transfected cells pre-gated on
mNeon. The gate shows the percentage of cells with active caspase-3.
UL36 Expression Rescues 1M36.MCMV
Replication In vivo
We have previously shown that M36 deletion mutants have
severe growth defects in vivo (Cicin-Sain et al., 2005), which
can be rescued by another gene that inhibits death-receptor
apoptosis (Cicin-Sain et al., 2008; Ebermann et al., 2012). To
confirm that this was indeed due to the lack of the M36 protein
(pM36), and not to cis effects, we generated a novel mutant,
where the M36 start codon was swapped with a stop codon
(see Supplementary Figure 1). Whole viral genome sequence
was validated by NGS, and no additional mutations were
observed (data not shown). This mutant was used throughout
the manuscript and is indicated as1M36.MCMV. To evaluate if
UL36 can rescue the in vivo replication of the MCMV that lacks
the M36 protein, MCMVUL36 was used to infect BALB/c and
C57BL/6 and the growth of the virus was quantified in different
organs and compared with the MCMVWT and1M36.MCMV in
two independent experiments.
BALB/c mice were infected via the intraperitoneal (i.p.) route
with 2 × 105 PFU of MCMVWT, 1M36.MCMV or MCMVUL36
and organ homogenates were assayed for infectious virus by
plaque assay on days 5 and 21 post-infection (Figure 3). At day
five post infection, the M36 deletion mutant showed a complete
absence of growth in the spleen, lower virus titer in the liver
and no loss of titer in the lungs (Figure 3). The MCMVUL36
virus, on the other hand, was able to spread to nearby organs
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FIGURE 2 | Recombinant MCMVUL36 generation and characterization. (A) The MCMV M36 ORF (around ∼47 to ∼49 kbp) was replaced with the UL36 ORF in the
MCMV genome by homologous En passant recombination. Note that M36 intron was left unchanged in the recombinant MCMVUL36 genome. (B) NIH3T3 cells were
infected with indicated viruses at an MOI of 0.1. The supernatants were collected at indicated days post infection and titrated on C57BL/6 MEFs. Values show the
mean of three biological replicates and error bars represent SEM. (C) Reverse transcription PCR was performed to detect UL36 mRNA in lysates of HEK293 cells
transfected with mNeon-P2A-mycTAG-UL36-N1 or the parental vector or NIH3T3 cells infected with MCMVWT and MCMVUL36 at MOI of 1. (D) Western blot for
pUL36 in the cell lysate of cells transfected or infected as in (C).
from the site of administration and establish virus titers similar
to the wild-type virus, indicating that the UL36 gene expression
compensated for the absence of the M36 gene and rescued
MCMV growth in spleen and liver at day five post infection.
On day 21 post infection, virus titers decreased in all organs
except the salivary glands, where titers were considerably higher
(Figure 3). MCMVWT showed the highest titers in this organ,
while1M36.MCMVwas not detected.MCMVUL36 replication in
the salivary glands was detected in all infected animals, although
the titers were lower than upon MCMVWT infection. Thus, the
expression of the UL36 gene helped the mutant virus spread from
the site of infection to distant organs and partially rescued the
viral growth in the salivary glands.
To exclude the possibility that UL36-mediated rescue of virus
growth is limited to a single inbred mouse strain, we repeated
our experiment in C57BL/6 mice. Due to the inherent resistance
of C57BL/6 mice against MCMV infection (Brown et al., 2001),
they were i.p. infected with a higher infectious dose (106 PFU).
As in the BALB/c strain, 1M36.MCMV did not show severe
growth defect in the lungs of the C57BL/6 mice on day five post
infection (Figure 4). However, the virus growth was attenuated
in the liver and spleen. Viral growth was completely rescued by
UL36 expression on day five post infection. In contrast to BALB/c
mice, titers of MCMVWT and MCMVUL36 were relatively high in
the liver and spleen of C57BL/6 mice on day 21 post infection,
but1M36.MCMV was not detected in any organ on day 21 post
infection (Figure 4). Replication ofMCMVUL36 was also partially
rescued in the salivary glands, similar to the rescue observed in
BALB/c mice.
UL36 Inhibits Apoptosis and Rescues
1M36.MCMV Growth in Murine
Macrophages
1M36.MCMV is not only growth deficient in vivo, but also
in vitro in macrophage cell cultures (Menard et al., 2003),
or in those where macrophages are present (Ebermann et al.,
2012). Concomitantly, macrophage cultures infected with M36-
deficient MCMV underwent massive apoptosis (Menard et al.,
2003), and apoptosis inhibition rescued its growth in these
cells (Cicin-Sain et al., 2008). Therefore, it was plausible that
MCMVUL36 in vivo growth would be reflected in its ability to
inhibit apoptosis and growth in macrophage cell cultures.
The growth of MCMVUL36 was compared with MCMVWT
and 1M36.MCMV in three different murine macrophage lines:
RAW264.7, J774A.1, and IC-21. J774A.1 and IC-21 cell lines were
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FIGURE 3 | UL36 rescues growth of 1M36 MCMV in BALB/c mice. BALB/c mice were intraperitoneally infected with 2 × 105 PFUs of indicated viruses. Virus titers in
liver, lungs, spleen and salivary gland were determined by organ titration at 5 and 21 day post infection. Each symbol indicates one mice and the solid line represents
the median value. The dashed line represents the detection limit for organ titration. (ns – p > 0.05, *p < 0.05, **p < 0.01, Mann Whitney test).
infected at an MOI of 1 and RAW264.7 cell line was infected
with 2.5 PFU per cell, due to its low permissiveness for MCMV
infection (data not shown). The 1M36.MCMV showed growth
defects in all macrophage lines (Figure 5). The difference in
the growth rate of wild-type MCMV and 1M36.MCMV was
smaller in RAW264.7 than in the other two cell lines (Figure 5A).
In RAW264.7 cells, 1M36.MCMV virus showed some growth
during early days of infection, but less than either MCMVWT
or MCMVUL36. The 1M36.MCMV did not grow at all in J774.1
(Figure 5B) and IC-21 cells (Figure 5C), as titers continuously
decreased in these macrophage cell lines (Figures 5B,C). The
expression of the UL36 gene rescued the virus growth, and
MCMVUL36 growth kinetics were comparable to MCMVWT in
all three macrophage cell lines tested.
The growth defects of M36-deficient virus in murine
macrophages are due to apoptosis upon infection (Menard
et al., 2003; Cicin-Sain et al., 2008). Therefore, it was reasonable
to assume that the rescue of growth by UL36 expression
would be linked to its ability to inhibit apoptosis in the
context of MCMV infection. Apoptosis in MCMV-infected
macrophages was quantified by analyzing caspase-3 activation or
cell surface expression of phosphatidylserine by flow cytometry.
Macrophages were infected with MCMVUL36, 1M36.MCMV, or
MCMVWT at an MOI of 1 and apoptosis assays were performed
24 h later. IC-21 cells infected with 1M36.MCMV showed the
highest level of apoptosis in both assays, with more than 60%
of cells positive for apoptosis markers (Figure 6), whereas, the
percentages of apoptotic cells in the virus-infected RAW 264.7
and J774A.1 cell lines were much lower. UL36 clearly inhibited
the induction of apoptosis in the macrophages, sinceMCMVUL36
infection resulted in a percentage of apoptotic cells that was
similar to the one observed upon wild-type MCMV infection.
Taken collectively, the data argued that the expression of the
UL36 gene in the mutant virus lacking the M36 gene inhibits
apoptosis and rescues viral growth in vitro and in vivo by
engaging the very same molecular target.
pUL36 Forms Complex with Murine
Pro-Caspase-8
The pUL36 protein blocks the Fas-mediated apoptosis in human
cells by binding to pro-caspase-8 and inhibiting its activation
(17). Since the UL36 expression from the 1M36.MCMV
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FIGURE 4 | UL36 rescues the growth of 1M36 MCMV in C57BL/6 mice. C57BL/6 mice were infected with 106 PFU of indicated viruses via the intraperitoneal route.
The virus titers in liver, lungs, spleen and salivary gland were determined by organ titration at 5 and 21 day post infection. Each symbol indicates one mice and the
solid line represents the median value. The dashed line represents the detection limit for organ titration. (ns – p > 0.05, *p < 0.05, **p < 0.01, Mann Whitney test).
FIGURE 5 | UL36 protein rescues growth of 1M36 MCMV in macrophages. Growth of MCMVWT, 1M36.MCMV and MCMVUL36 was compared in (A) RAW 264.7,
(B) J774A.1, and (C) IC-21 macrophage cell lines. RAW 264.7 cells were infected at an MOI of 2.5 while J774.A and IC-21 were infected at 1 MOI. The infectious
virus in supernatants was quantified plaque assay on C57BL/6 MEF cells. Values represent means of three biological replicates, while error bars indicate SEM.
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FIGURE 6 | Virus induced apoptosis in macrophages. The indicated macrophages were infected with specified viruses at an MOI of 1 and apoptosis was quantified 1
day post infection. Most experiments were performed at least twice and typical data are shown. (A) Active caspase 3 was quantified by antibody labeling and
cytofluorometric analysis to asses apoptosis induced by virus infection. (B) The plasma membrane eversion of phosphatidylserine was detected by staining with
fluorescently labeled Annexin V. Indicated points and horizontal lines on graph represent independent biological replicates and mean values respectively. (C) IC-21
cells were infected with indicated viruses at an MOI of 1 and analyzed 24 h post infection. Bar 200 µm.
prevented apoptosis in infected murine macrophages, we tested
if UL36 physically interacts with murine caspase-8. To determine
this, co-immunoprecipitation assay was performed. For this
purpose, NIH3T3 cells were transfected with myc-tagged UL36.
Cell lysates were immunoprecipitated with anti-myc antibody
coated beads and protein complexes were separated by SDS
PAGE. Immunoblot analysis was performed using anti-caspase-
8 and anti-UL36 antibodies. UL36 was detected in anti-
myc immunoprecipitates from myc-tagged-UL36 transfected
NIH3T3 cells, whereas it was not detected in control cells
transfected with empty vector. Also, pro-caspase-8 was detected
in the immunoprecipitates from UL36-transfected NIH3T3
murine cells but not from the controls, indicating that the protein
pUL36 interacted with the murine pro-caspase-8 (Figure 7).
DISCUSSION
Cytomegalovirus is an extremely slowly growing virus, which
necessitates antiapoptotic functions to protect the infected
cell from cell-intrinsic apoptosis induced by metabolic stress
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FIGURE 7 | pUL36 forms complex with pro-caspase-8. Lysates from myc
tagged UL36 or empty vector transfected cells were immunoprecipitated (IP)
with the anti-myc antibody. Lanes designated IP are proteins bound with
anti-myc antibody. Fifty-five kilo Daltons band of pro-caspase-8 was detected
by immunoblot analysis using antibodies against murine caspase-8 1G12.
(Goldmacher et al., 1999; Brune et al., 2003) but also from
apoptosis triggered by extrinsic signaling (Skaletskaya et al., 2001;
Mccormick et al., 2003, 2010; Menard et al., 2003; Ebermann
et al., 2012). While previous work demonstrated that the MCMV
gene M36 (Menard et al., 2003; Cicin-Sain et al., 2008) and the
HCMV gene UL36 are required for viral growth in macrophages
(Mccormick et al., 2010), and that both gene products target
the same signaling pathway by binding to the highly conserved
host target protein caspase-8 (Skaletskaya et al., 2001; Menard
et al., 2003), it has remained unclear whether their function is
interchangeable, and if UL36 would be functional in murine cells.
We show here that UL36 may be detected along with caspase
8 in the enriched immunoprecipitates of the transfected cells,
although its concentrations were too low to be detectable in
whole cell lysates. Therefore, our results indicate binding a highly
conserved molecular interaction between M36/UL36 proteins
and murine/human caspase-8 targets.
Similar approaches were conducted to study the HCMV
chemokine receptor (CKR) homologs UL33 and US28, or
the HCMV protein kinase UL97. Farrell et al. developed
1M33/UL33 and 1M33/UL28 MCMV viruses, to replace the
MCMV CKR homolog M33 with HCMV genes UL33 or UL28
(Farrell et al., 2011). Although, M33 and UL33 share homology,
UL33 could not adequately complement the M33 gene and the
recombinant virus suffered from in vivo growth defect. This hints
that viral CKR homologs may be highly optimized to work in the
host species that they co-evolved with. Similarly, UL97-MCMV
was developed to study the UL97 protein, a protein kinase
of HCMV that phosphorylates the antiviral drug ganciclovir,
resulting in its targeted inhibition of DNA replication in HCMV-
infected cells. UL97 protein partially substituted the M97 protein
and rescued the growth deficit seen upon 1M97.MCMV in
vivo infection of mice (Wagner et al., 2000). In spite of the
aforementioned caveats, these studies provide us with tools to
study HCMV genes in vivo. Similarly, MCMVUL36 can be used to
study the pUL36 (vICA) in the context of virus infection in vivo,
because our experiments with MCMVUL36 demonstrated that
UL36 functionally replaces the MCMV M36 gene, and largely
rescues the growth defect shown by1M36.MCMV.
Zymosan activated macrophages have been shown to
induce apoptosis in primary fibroblasts (MEFs) infected
with 1M36.MCMV, by secreting TNFα (Ebermann et al.,
2012). However, it remains unclear how infection with
1M36.MCMV, but notMCMVwild-type orMCMVUL36 induces
apoptosis in the macrophage monocultures upon infection. One
possible explanation might be that MCMV-infection deactivates
macrophages, which release pro-apoptotic ligands that activate
the FADD-mediated machinery and induce apoptosis in a
paracrine fashion, but further studies are required to elucidate
the underlying mechanism. The MCMVUL36 completely rescued
the apoptosis in RAW264.7 and J774A.1, but the inhibition of
apoptosis in the IC-21 cells was not complete. The incomplete
inhibition of apoptosis, as compared to wild-type MCMV
infection, might be explained by different affinity of binding of
UL36 andM36 protein to the murine pro-caspase-8. Considering
that the murine and human caspases have inherent differences
in their sequences, where the homology between the human and
the murine caspase-8 is 76% (Van De Craen et al., 1998), and
that the sequence homology between M36 and UL36 is only
19% (Mccormick et al., 2003), it is reasonable to assume that the
binding affinity of UL36 to the murine caspase-8 is different than
that of M36. However, this aspect needs clarification by more
detailed studies of M36 and UL36 binding to murine caspase-8.
We have previously shown that the growth of 1M36.MCMV
can be rescued by overexpression of a dominant-negative FADD
variant (FADDDN) introduced ectopically in the MCMV genome
and driven by the CMV i.e., promoter (Cicin-Sain et al., 2008).
FADDDN contains the death domain to associate with trimeric
complex of death receptors, but lacks the N-terminal death
effector domain required to activate caspase-8 (Chinnaiyan
et al., 1995). Thus, it blocks caspase-8 mediated signaling
and was able to compensate for the absence of M36 in the
infected cell (Chinnaiyan et al., 1996). The in vivo fitness of
the 1M36.MCMV was not completely rescued by FADDDN
and 1M36.FADDDN.MCMV showed moderate attenuation in
some organs (Cicin-Sain et al., 2008). The attenuation of
1M36.FADDDN.MCMV may either reflect differences in the
molecular targets of M36 and FADDDN, or differences in
expression kinetics, where FADDDN is overexpressed by an
exceedingly strong ectopic promotor. In term of expression
kinetics, our current model differs from the previous one,
because the homologous UL36 protein was expressed via the
M36 promotor, and the splice acceptor and donor sites of M36
remained intact, arguing that splice efficiency of M36 is retained.
This excludes any confounding factors associated with gene
expression kinetics or amount, indicating that UL36 expression
levels equal to that of M36 are enough to protect the infected
cell from apoptosis and confer growth fitness. MCMVUL36
completely rescued the virus growth in liver and spleen. However,
the UL36 expression only partially rescued the growth in the
salivary glands. The low titers in the salivary glands might be
either due to growth defects or to the inability of the virus to
spread to distant organs from the initial site of infection. It
has been shown that the M36 gene plays an important role in
the dissemination of MCMV from the initial site of infection
(Cicin-Sain et al., 2005) and monocytes are regarded as the
vehicle for MCMV dissemination to distant tissues (Smith et al.,
2004; Daley-Bauer et al., 2014). The monocytes do not support
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productive viral replication, but upon their migration into tissues
they differentiate intomacrophages, upon which productive virus
replication initiates. The incomplete inhibition of apoptosis by
MCMVUL36 (Figure 6) might therefore partly explain the poor
in vivo spread and the incomplete rescue of virus replication in
salivary glands. However, further experiments are required to
validate this hypothesis.
Notwithstanding the moderate loss of fitness in salivary
glands, the recombinant MCMVUL36 provides a novel tool
to study the UL36 gene and demonstrates that UL36 may
act as a determinant of viral fitness in the context of in
vivo infection. In combination with previous studies, our
data also suggest a vital role of the UL36 gene for in
vivo fitness of HCMV (Skaletskaya et al., 2001; Mccormick
et al., 2003, 2010). While antiviral substances targeting viral
replication are available, these drugs exhibit toxic side-effects
(e.g., suppression of hematopoiesis) and may result in escape
mutations of the target genes (Ramanan and Razonable, 2013).
The suggested vital role of the UL36 gene for viral in vivo
fitness and the fact that M36 and UL36 exert their anti-apoptotic
function by direct binding to pro caspase-8 (Skaletskaya et al.,
2001; Menard et al., 2003), presents a novel antiviral target;
targeting the anti-apoptotic function of UL36 could provide
a new class of anti-viral compounds. As UL36 and M36
proteins engage identical molecular targets, the developed model
can help studies of anti-viral compounds against the UL36
gene in vivo. The system will hence allow us to validate
pharmacokinetics and toxicity properties of promising lead
candidates targeting UL36 in the context of MCMV infection
while additionally giving insight into their antiviral efficacy
in vivo. This experimental model therefore, has a strong potential
to support studies of human biology and applications in clinical
medicine.
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